Short Interest Change: Is Buying Auris Medical Holding AG (NASDAQ:EARS) Here Good Idea?

December 1, 2016 - By Vivian Park   ·   0 Comments

Short Interest Change: Is Buying Auris Medical Holding AG (NASDAQ:EARS) Here Good Idea?

The stock of Auris Medical Holding AG (NASDAQ:EARS) registered a decrease of 11.81% in short interest. EARS’s total short interest was 572,600 shares in December as published by FINRA. Its down 11.81% from 649,300 shares, reported previously. With 243,300 shares average volume, it will take short sellers 2 days to cover their EARS’s short positions. The short interest to Auris Medical Holding AG’s float is 4.05%. The stock closed at $1.2 during the last session. It is down 69.31% since April 28, 2016 and is downtrending. It has underperformed by 75.23% the S&P500.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical firm focused on the development of products for the treatment of inner ear disorders. The company has a market cap of $39.95 million. The Company’s advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment from the United States Food and Drug Administration. It currently has negative earnings. The Company’s second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL).

Auris Medical Holding AG (NASDAQ:EARS) Ratings Coverage

Out of 2 analysts covering Auris Medical Holding AG (NASDAQ:EARS), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Auris Medical Holding AG has been the topic of 2 analyst reports since March 15, 2016 according to StockzIntelligence Inc. On Tuesday, March 15 the stock rating was maintained by Jefferies with “Buy”. As per Friday, August 19, the company rating was maintained by Needham.

EARS Company Profile

Auris Medical Holding AG, incorporated on April 15, 1998, is a holding and clinical-stage biopharmaceutical firm focused on the development of products for the treatment of inner ear disorders. The Company’s advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration (FDA). In approximately two Phase II clinical trials, AM-101 demonstrated a favorable safety profile and significant improvement in tinnitus loudness and other patient reported outcomes. The Company’s second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). In its Phase II clinical trial, AM-111 showed a favorable safety profile.

More important recent Auris Medical Holding AG (NASDAQ:EARS) news were published by: Marketwatch.com which released: “Auris Medical stock slumps 54% premarket as company says tinnitus trial missed …” on August 18, 2016, also Streetinsider.com published article titled: “Auris Medical Holding (EARS) Reports Keyzilen TACTT2 Trial Missed co-Primary …”, Bioworld.com published: “Auris Medical Gets $51M for Hearing Disorder Drugs” on April 17, 2013. More interesting news about Auris Medical Holding AG (NASDAQ:EARS) was released by: Marketwatch.com and their article: “Auris Medical Holding AG” with publication date: August 03, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Vivian Park


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>